OS-106 Safety and efficacy of pemafibrate (K-808), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with primary biliary cholangitis: twelve-week data from the randomized, placebo-controlled, PEMA-PBC dose-finding study

Journal of Hepatology 2026

View at publisher
Authors: Gideon Morris Hirschfield, Kris V. Kowdley, Marco Carbone, D. O. Jones, Albert Pares, Cynthia Levy, Shinji Shimoda, Andrey Belous, Ryohei Tanigawa, Hideki Suganami, Atsushi Tanaka
DOI: 10.1016/s0168-8278(26)00417-4
Cited by: 1

Fields of Study & Subjects

Liver Diseases and Immunity Drug Transport and Resistance Mechanisms Peroxisome Proliferator-Activated Receptors

Publication details

Journal / source
Journal of Hepatology
Publisher
Elsevier BV
Volume
84
Pages
S67–S68
Publication date
1 May 2026
Language
EN